Genmab Says Phase 3 EPCORE FL-1 Clinical Trial Met Dual Primary Endpoints In Patients With R/R FL
RefinitivOkuma süresi: 1 dakikadan kısa
Genmab A/S 
GMAB:
GENMAB ANNOUNCES PHASE 3 EPCORE® FL-1 CLINICAL TRIAL MET DUAL PRIMARY ENDPOINTS IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)
GENMAB - FDA HAS ACCEPTED FOR PRIORITY REVIEW NEW SBLA FOR EPCORITAMAB PLUS R(2), WITH ACTION DATE OF NOVEMBER 30
Bu haberi okumak için giriş yapın veya sonsuza kadar ücretsiz bir hesap oluşturun